The future is bright for mRNA science.
Scientists have been studying whether it is possible to instruct a patient’s own cells to produce proteins that have the potential to treat a wide range of conditions. This technology has the potential to significantly impact the way we treat and prevent diseases in years ahead.
Presenters include Moderna’s US-based Chief Medical Officer, Dr Paul Burton, who will discuss some exciting advancements across the mRNA vaccine and therapeutic development pipeline, including new data from Moderna's personalised cancer vaccine trials for melanoma and future plans for this potentially transformational therapy for cancer.
Professor Grant McArthur will host a panel discussion of expert oncology, immunology, government and consumer specialists, providing their perspectives on mRNA and what the future may hold.
This exciting event will cover:
Paul Burton MD PhD FRCP, is Chief Medical Officer at Moderna Therapeutics, a role he has held since July 2021 with global responsibility for all medical strategy as well as patient safety and pharmacovigilance. Prior to joining Moderna, Paul spent 16 years at Johnson and Johnson, most recently as Chief Global Medical Affairs Officer. Paul has over 20 years of biopharmaceutical industry experience. He received his MD and PhD from the University of London, with clinical training in cardiothoracic surgery.
Professor Sherene Loi is a Medical Oncologist specialising in breast cancer treatment and a clinician scientist (group leader) with expertise in genomics, immunology and drug development at Peter MacCallum Cancer Centre. She is recognised internationally as a leading clinician scientist whose work has led to new insights into the breast cancer immunology field. She Co-Chairs the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland, and currently holds the Inaugural National Breast Cancer Foundation (NBCF) of Australia Endowed Chair. In 2021 she received one of The Prime Ministers’ Awards for Science.
